Famvir Patent Settlement: 17 Months After At-Risk Launch, Teva Must Pay Novartis
Teva's at-risk strategy produces another muddled outcome as the generic firm now owes Novartis royalties on U.S. sales of its generic version of the herpes drug.
Teva's at-risk strategy produces another muddled outcome as the generic firm now owes Novartis royalties on U.S. sales of its generic version of the herpes drug.